Amoy Diagnostics (AmoyDx) has entered a strategic partnership with Servier to co-develop a companion diagnostic (CDx) test for detecting isocitrate dehydrogenase (IDH) 1 and 2 gene mutations.
The partnership aims to develop a diagnostic tool for identifying IDH gene mutations, which will be used in the research for a novel drug, "vorasidenib." This drug is designed to inhibit these mutations and is expected to be used to treat Diffuse Lower Grade Glioma patients who carry these mutations in China. AmoyDx will use its Next-Generation Sequencing (NGS) technology for this development and support the drug's registration and commercialization in mainland China.
China-based Amoy Diagnostics specializes in molecular diagnostics for oncology precision medicine. The company offers a range of diagnostic products, including PCR, NGS, FISH, and IHC assays, under proprietary brands such as ADx-ARMS, Super-ARMS, and ADx-HANDLE. AmoyDx also operates the Xiamen Amoy Medical Laboratory and the Shanghai Xiawei Medical Laboratory, which provide third-party clinical inspection services.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.